Effect of Adjuvant Therapy on Oncologic Outcomes of Surgically Confirmed Stage I Uterine Carcinosarcoma: a Turkish Gynecologic Oncology Study
| dc.contributor.author | Altın, Duygu | |
| dc.contributor.department | Tıp Fakültesi | tr_TR |
| dc.date.accessioned | 2020-11-13T06:08:07Z | |
| dc.date.available | 2020-11-13T06:08:07Z | |
| dc.date.issued | 2019 | |
| dc.description.abstract | Background: Uterine carcinosarcoma is rare neoplasm that mostly presents as metastatic disease. Stage is one of the most important prognostic factor, however, the management of the early stage uterine carcinosarcoma is still controversial. Aims: To evaluate prognostic factors, treatment options, and survival outcomes in patients with surgically approved stage I uterine carcinosarcoma. Study design: Cross-sectional study. Methods: Data of 278 patients with uterine carcinosarcoma obtained from four gynecologic oncology centers were reviewed, and 70 patients with approved stage I uterine carcinosarcoma after comprehensive staging surgery were studied. Results: The median age of the entire cohort was 65 years (range; 39-82). All patients underwent both pelvic and paraaortic lymphadenectomy. Forty-one patients received adjuvant therapy. The median follow-up time was 24 months (range; 1-129). Nineteen (27.1%) patients had disease failure. The 3-year disease-free survival and cancer-specific survival of the entire cohort was 67% and 86%, respectively. In the univariate analysis, only age was significantly associated with disease-free survival (p=0.022). There was no statistical significance for disease-free survival between observation and receiving any type of adjuvant therapy following staging surgery. Advanced age (<75 vs ≥75 years) was the only independent prognostic factor for recurrence (hazard ratio: 3.8, 95% CI=1.10-13.14, p=0.035) in multivariate analysis. None of the factors were significantly associated with cancer-specific survival. Conclusion: Advanced age was the only independent factor for disease-free survival in stage I uterine carcinosarcoma. Performing any adjuvant therapy following comprehensive lymphadenectomy was not related to the improved survival of the stage I disease. | tr_TR |
| dc.identifier.endpage | 234 | tr_TR |
| dc.identifier.issue | 4 | tr_TR |
| dc.identifier.startpage | 229 | tr_TR |
| dc.identifier.uri | https://doi.org/10.4274/balkanmedj.galenos.2019.2018.12.75 | tr_TR |
| dc.identifier.uri | http://hdl.handle.net/20.500.12575/72339 | |
| dc.identifier.volume | 36 | tr_TR |
| dc.language.iso | en | tr_TR |
| dc.relation.isversionof | 10.4274/balkanmedj.galenos.2019.2018.12.75 | tr_TR |
| dc.relation.journal | Balkan Med J . | tr_TR |
| dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | tr_TR |
| dc.subject | Adjuvant | tr_TR |
| dc.subject | carcinosarcoma | tr_TR |
| dc.subject | chemotherapy | tr_TR |
| dc.title | Effect of Adjuvant Therapy on Oncologic Outcomes of Surgically Confirmed Stage I Uterine Carcinosarcoma: a Turkish Gynecologic Oncology Study | tr_TR |
| dc.type | Article | tr_TR |